Ying Du Sells 23,939 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 23,939 shares of Zai Lab stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $17.90, for a total value of $428,508.10. Following the transaction, the chief executive officer now owns 1,142,833 shares in the company, valued at approximately $20,456,710.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ying Du also recently made the following trade(s):

• On Tuesday, April 2nd, Ying Du sold 5,787 shares of Zai Lab stock. The stock was sold at an average price of $16.15, for a total value of $93,460.05.

Zai Lab Trading Down 1.1 %

Shares of ZLAB opened at $17.33 on Friday. The firm has a market cap of $1.72 billion, a P/E ratio of -4.97 and a beta of 1.16. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $32.60. The company’s 50-day moving average price is $18.36 and its 200 day moving average price is $20.19.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $0.38. The firm had revenue of $87.15 million for the quarter, compared to analyst estimates of $77.07 million. Zai Lab had a negative net margin of 116.45% and a negative return on equity of 40.21%. During the same period in the previous year, the firm earned ($0.51) EPS. Equities research analysts forecast that Zai Lab Limited will post -2.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a report on Tuesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $64.57.

Institutional Trading of Zai Lab

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its position in Zai Lab by 1,923.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,550 shares of the company’s stock valued at $70,000 after acquiring an additional 2,424 shares in the last quarter. BNP Paribas Financial Markets grew its position in Zai Lab by 51.2% in the 1st quarter. BNP Paribas Financial Markets now owns 2,671 shares of the company’s stock valued at $43,000 after acquiring an additional 904 shares in the last quarter. Headlands Technologies LLC acquired a new position in Zai Lab in the 1st quarter valued at about $64,000. Sectoral Asset Management Inc. grew its position in Zai Lab by 33.3% in the 4th quarter. Sectoral Asset Management Inc. now owns 4,000 shares of the company’s stock valued at $109,000 after acquiring an additional 1,000 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Zai Lab in the 4th quarter valued at about $116,000. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.